Drug Profile
Research programme: leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX Consortium
Alternative Names: MGN 1331; MIDGE-based leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX ConsortiumLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator LEISHDNAVAX Consortium; Mologen
- Developer Mologen
- Class DNA vaccines; Leishmaniasis vaccines; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Leishmaniasis
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Leishmaniasis in Europe (Parenteral)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Leishmaniasis in Europe (Parenteral)
- 01 Nov 2017 Mologen reactivates preclinical development for Leishmaniasis in Europe (Parenteral) upon receiving GHIT funding